NCT05021120View on ClinicalTrials.gov

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

October 1, 2024

Study Completion Date

May 27, 2025

Conditions
Advanced or Metastatic Solid Tumours
Interventions
DRUG

AK127

Subjects will receive AK127 by intravenous administration

DRUG

AK104

After AK127 infusion, on the same day subjects will receive AK104 by intravenous administration

Trial Locations (5)

Unknown

Ashford Cancer Centre Research, Adelaide

Austin Health, Melbourne

Monash Health, Melbourne

Southside Cancer Care Centre, Sydney

The Kinghorn Cancer Centre, St Vincents Hospital Sydney, Sydney

All Listed Sponsors
lead

Akesobio Australia Pty Ltd

INDUSTRY